LILRB4/CD85k/ILT3 Protein, Cynomolgus (HEK293, Fc)

LILRB4/CD85k/ILT3 Protein, Cynomolgus (HEK293, Fc) is the recombinant cynomolgus-derived LILRB4/CD85k/ILT3 protein, expressed by HEK293, with C-hFc tag.

LILRB4/CD85k/ILT3, an inhibitory receptor intricately involved in immune regulation, plays a crucial role in down-regulating immune responses. It serves as a receptor for FN1 and integrin ITGAV/ITGB3, exerting inhibitory effects on IgE-mediated mast cell activation and KITLG/SCF-mediated mast cell activation. Through its interaction with ITGAV/ITGB3, LILRB4/ILT3 further inhibits antibody production by memory and marginal zone B cells, likely by suppressing their differentiation into plasma cells. This multifaceted receptor extends its inhibitory influence to diverse immune functions, such as suppressing IFNG production by CD8 T cells, CD4 T cells, and natural killer cells, as well as inhibiting antigen presentation by dendritic cells to T cells, preventing T cell activation. Additionally, LILRB4/ILT3 effectively inhibits lipopolysaccharide-mediated neutrophil-dependent vascular injury and contributes to the suppression of the allergic inflammatory response by impeding the infiltration of neutrophils and eosinophils while preventing mast cell degranulation. Its interactions, particularly when tyrosine phosphorylated, with SH2 domain-containing phosphatases PTPN6/SHP-1 and PTPN11/SHP-2 enhance the inhibition of mast cell activation.

Cynomolgus

HEK293

C-hFc

XP_015297198.1 (Q22-E259)

/

Partial

Approximately 60-66 kDa,based on SDS-PAGE under reducing conditions,120-140 kDa,based on SDS-PAGE under non-reduced conditions,due to the glycosylation.

Greater than 85% as determined by reducing SDS-PAGE.

<1 EU/μg, determined by LAL method.